Cargando…
Reduction in Urinary Chemokine (C-C Motif) Ligand 2 (CCL2) After Surgery-Induced Weight Loss
Kidney dysfunction, a deleterious effect of obesity, is now recognized as a relevant health risk. Chemokine (C-C Motif) Ligand 2 (CCL2) is one of the critical chemokines that play a vital role in the development of obesity-related metabolic disease. We aim to measure the changes in urinary CCL2 in o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972822/ https://www.ncbi.nlm.nih.gov/pubmed/31964990 http://dx.doi.org/10.1038/s41598-020-57763-8 |
_version_ | 1783489914847887360 |
---|---|
author | Said, Surita Binti Loo, Guo Hou Kosai, Nik Ritza Rajan, Reynu Mohd, Rozita Wahab, Asrul Abdul Shah, Shamsul Azhar |
author_facet | Said, Surita Binti Loo, Guo Hou Kosai, Nik Ritza Rajan, Reynu Mohd, Rozita Wahab, Asrul Abdul Shah, Shamsul Azhar |
author_sort | Said, Surita Binti |
collection | PubMed |
description | Kidney dysfunction, a deleterious effect of obesity, is now recognized as a relevant health risk. Chemokine (C-C Motif) Ligand 2 (CCL2) is one of the critical chemokines that play a vital role in the development of obesity-related metabolic disease. We aim to measure the changes in urinary CCL2 in our patients before and after their bariatric procedure and examine the correlation between CCL2 and renal function. A prospective cohort study was conducted at our teaching university hospital. Ethics approval was obtained from our institutional review board. Patients with a BMI of ≥37.5 kg/m(2) with no history of renal disease were included. They underwent single anastomosis gastric bypass (SAGB), Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG), all performed via laparoscopic approach. Venous blood and urine samples were obtained preoperatively and six months after surgery. A total of 58 patients were recruited, with SG being performed in 74.1% of patients. At six-months follow-up, median (IQR) body weight reduced from 101.35 kgs (20.25) to 76.95 kg (24.62) p < 0.001. The mean (SD) estimated glomerular filtration rate (eGFR) improved from 96.26 ± 14.97 to 108.06 ± 15.00 mL/min/1.73 m(2), p < 0.001. The median (IQR) urinary CCL2 levels reduced from 15.2 pg/ml (10.77) to 4.30 pg/ml (4.27) p < 0·001. There is a significant correlation between the reduction of BMI and the reduction of urinary CCL2 (r = −0.220, p = 0.048). We also found a significant correlation between the reduction of urinary CCL2 with the reduction of urine ACR (r = −0.240, p = 0.035). Urinary CCL2 is a promising biomarker that can be used to assess improvement in renal function in obese patients after bariatric surgery. |
format | Online Article Text |
id | pubmed-6972822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-69728222020-01-27 Reduction in Urinary Chemokine (C-C Motif) Ligand 2 (CCL2) After Surgery-Induced Weight Loss Said, Surita Binti Loo, Guo Hou Kosai, Nik Ritza Rajan, Reynu Mohd, Rozita Wahab, Asrul Abdul Shah, Shamsul Azhar Sci Rep Article Kidney dysfunction, a deleterious effect of obesity, is now recognized as a relevant health risk. Chemokine (C-C Motif) Ligand 2 (CCL2) is one of the critical chemokines that play a vital role in the development of obesity-related metabolic disease. We aim to measure the changes in urinary CCL2 in our patients before and after their bariatric procedure and examine the correlation between CCL2 and renal function. A prospective cohort study was conducted at our teaching university hospital. Ethics approval was obtained from our institutional review board. Patients with a BMI of ≥37.5 kg/m(2) with no history of renal disease were included. They underwent single anastomosis gastric bypass (SAGB), Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG), all performed via laparoscopic approach. Venous blood and urine samples were obtained preoperatively and six months after surgery. A total of 58 patients were recruited, with SG being performed in 74.1% of patients. At six-months follow-up, median (IQR) body weight reduced from 101.35 kgs (20.25) to 76.95 kg (24.62) p < 0.001. The mean (SD) estimated glomerular filtration rate (eGFR) improved from 96.26 ± 14.97 to 108.06 ± 15.00 mL/min/1.73 m(2), p < 0.001. The median (IQR) urinary CCL2 levels reduced from 15.2 pg/ml (10.77) to 4.30 pg/ml (4.27) p < 0·001. There is a significant correlation between the reduction of BMI and the reduction of urinary CCL2 (r = −0.220, p = 0.048). We also found a significant correlation between the reduction of urinary CCL2 with the reduction of urine ACR (r = −0.240, p = 0.035). Urinary CCL2 is a promising biomarker that can be used to assess improvement in renal function in obese patients after bariatric surgery. Nature Publishing Group UK 2020-01-21 /pmc/articles/PMC6972822/ /pubmed/31964990 http://dx.doi.org/10.1038/s41598-020-57763-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Said, Surita Binti Loo, Guo Hou Kosai, Nik Ritza Rajan, Reynu Mohd, Rozita Wahab, Asrul Abdul Shah, Shamsul Azhar Reduction in Urinary Chemokine (C-C Motif) Ligand 2 (CCL2) After Surgery-Induced Weight Loss |
title | Reduction in Urinary Chemokine (C-C Motif) Ligand 2 (CCL2) After Surgery-Induced Weight Loss |
title_full | Reduction in Urinary Chemokine (C-C Motif) Ligand 2 (CCL2) After Surgery-Induced Weight Loss |
title_fullStr | Reduction in Urinary Chemokine (C-C Motif) Ligand 2 (CCL2) After Surgery-Induced Weight Loss |
title_full_unstemmed | Reduction in Urinary Chemokine (C-C Motif) Ligand 2 (CCL2) After Surgery-Induced Weight Loss |
title_short | Reduction in Urinary Chemokine (C-C Motif) Ligand 2 (CCL2) After Surgery-Induced Weight Loss |
title_sort | reduction in urinary chemokine (c-c motif) ligand 2 (ccl2) after surgery-induced weight loss |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972822/ https://www.ncbi.nlm.nih.gov/pubmed/31964990 http://dx.doi.org/10.1038/s41598-020-57763-8 |
work_keys_str_mv | AT saidsuritabinti reductioninurinarychemokineccmotifligand2ccl2aftersurgeryinducedweightloss AT looguohou reductioninurinarychemokineccmotifligand2ccl2aftersurgeryinducedweightloss AT kosainikritza reductioninurinarychemokineccmotifligand2ccl2aftersurgeryinducedweightloss AT rajanreynu reductioninurinarychemokineccmotifligand2ccl2aftersurgeryinducedweightloss AT mohdrozita reductioninurinarychemokineccmotifligand2ccl2aftersurgeryinducedweightloss AT wahabasrulabdul reductioninurinarychemokineccmotifligand2ccl2aftersurgeryinducedweightloss AT shahshamsulazhar reductioninurinarychemokineccmotifligand2ccl2aftersurgeryinducedweightloss |